Declared Dividend • Jul 25
Final dividend of JP¥17.50 announced Shareholders will receive a dividend of JP¥17.50. Ex-date: 29th September 2026 Payment date: 11th December 2026 Dividend yield will be 3.2%, which is higher than the industry average of 1.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. Reported Earnings • May 20
Full year 2026 earnings released: JP¥52.27 loss per share (vs JP¥22.60 profit in FY 2025) Full year 2026 results: JP¥52.27 loss per share (down from JP¥22.60 profit in FY 2025). Revenue: JP¥252.3b (flat on FY 2025). Net loss: JP¥2.16b (down 323% from profit in FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Aankondiging • May 15
Xebio Holdings Co., Ltd., Annual General Meeting, Jun 26, 2026 Xebio Holdings Co., Ltd., Annual General Meeting, Jun 26, 2026. Aankondiging • May 10
Xebio Holdings Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026 Xebio Holdings Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥17.50 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 12 June 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.5%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.4%). Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: JP¥16.91 (vs JP¥44.88 in 3Q 2025) Third quarter 2026 results: EPS: JP¥16.91 (down from JP¥44.88 in 3Q 2025). Revenue: JP¥64.5b (up 2.2% from 3Q 2025). Net income: JP¥700.0m (down 63% from 3Q 2025). Profit margin: 1.1% (down from 3.0% in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Aankondiging • Dec 27
Xebio Holdings Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026 Xebio Holdings Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026 Declared Dividend • Dec 12
First half dividend of JP¥17.50 announced Shareholders will receive a dividend of JP¥17.50. Ex-date: 30th March 2026 Payment date: 12th June 2026 Dividend yield will be 3.4%, which is higher than the industry average of 1.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. New Risk • Nov 21
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 3.3% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 2.6% per year over the past 5 years. New Risk • Nov 18
New major risk - Revenue and earnings growth Earnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Paying a dividend despite being loss-making. Reported Earnings • Nov 18
Second quarter 2026 earnings released: JP¥2.95 loss per share (vs JP¥17.72 loss in 2Q 2025) Second quarter 2026 results: JP¥2.95 loss per share (improved from JP¥17.72 loss in 2Q 2025). Revenue: JP¥60.0b (flat on 2Q 2025). Net loss: JP¥122.0m (loss narrowed 84% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Aankondiging • Oct 31
Xebio Holdings Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025 Xebio Holdings Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025 Upcoming Dividend • Sep 22
Upcoming dividend of JP¥17.50 per share Eligible shareholders must have bought the stock before 29 September 2025. Payment date: 11 December 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%). Reported Earnings • Aug 09
First quarter 2026 earnings released: EPS: JP¥6.95 (vs JP¥63.23 in 1Q 2025) First quarter 2026 results: EPS: JP¥6.95 (down from JP¥63.23 in 1Q 2025). Revenue: JP¥64.3b (down 1.3% from 1Q 2025). Net income: JP¥288.0m (down 90% from 1Q 2025). Profit margin: 0.4% (down from 4.3% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Declared Dividend • Jul 09
Final dividend of JP¥17.50 announced Shareholders will receive a dividend of JP¥17.50. Ex-date: 29th September 2025 Payment date: 11th December 2025 Dividend yield will be 3.1%, which is higher than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (46% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Aankondiging • Jun 29
Xebio Holdings Co., Ltd. to Report Q1, 2026 Results on Aug 08, 2025 Xebio Holdings Co., Ltd. announced that they will report Q1, 2026 results on Aug 08, 2025 Reported Earnings • May 10
Full year 2025 earnings released: EPS: JP¥22.60 (vs JP¥58.63 in FY 2024) Full year 2025 results: EPS: JP¥22.60 (down from JP¥58.63 in FY 2024). Revenue: JP¥250.6b (up 3.4% from FY 2024). Net income: JP¥971.0m (down 63% from FY 2024). Profit margin: 0.4% (down from 1.1% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Aankondiging • May 09
Xebio Holdings Co., Ltd., Annual General Meeting, Jun 27, 2025 Xebio Holdings Co., Ltd., Annual General Meeting, Jun 27, 2025. Buy Or Sell Opportunity • Mar 26
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to JP¥1,300. The fair value is estimated to be JP¥1,083, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.7% over the last 3 years. Earnings per share has declined by 16%. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 12 June 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.5%). Aankondiging • Mar 01
Xebio Holdings Co., Ltd. to Report Fiscal Year 2025 Results on May 09, 2025 Xebio Holdings Co., Ltd. announced that they will report fiscal year 2025 results on May 09, 2025 Reported Earnings • Feb 16
Third quarter 2025 earnings released: EPS: JP¥44.88 (vs JP¥27.71 in 3Q 2024) Third quarter 2025 results: EPS: JP¥44.88 (up from JP¥27.71 in 3Q 2024). Revenue: JP¥63.1b (up 1.6% from 3Q 2024). Net income: JP¥1.91b (up 56% from 3Q 2024). Profit margin: 3.0% (up from 2.0% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Aankondiging • Jan 03
Xebio Holdings Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025 Xebio Holdings Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025 Reported Earnings • Nov 09
Second quarter 2025 earnings released: JP¥17.72 loss per share (vs JP¥0.77 profit in 2Q 2024) Second quarter 2025 results: JP¥17.72 loss per share (down from JP¥0.77 profit in 2Q 2024). Revenue: JP¥60.0b (up 3.9% from 2Q 2024). Net loss: JP¥769.0m (down JP¥803.0m from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 11 December 2024. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.4%). Aankondiging • Aug 29
Xebio Holdings Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024 Xebio Holdings Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024 Reported Earnings • Aug 14
First quarter 2025 earnings released: EPS: JP¥63.23 (vs JP¥44.94 in 1Q 2024) First quarter 2025 results: EPS: JP¥63.23 (up from JP¥44.94 in 1Q 2024). Revenue: JP¥65.1b (up 4.6% from 1Q 2024). Net income: JP¥2.79b (up 40% from 1Q 2024). Profit margin: 4.3% (up from 3.2% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 3% per year. Aankondiging • Jun 27
Xebio Holdings Co., Ltd. to Report Q1, 2025 Results on Aug 09, 2024 Xebio Holdings Co., Ltd. announced that they will report Q1, 2025 results on Aug 09, 2024 Valuation Update With 7 Day Price Move • May 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to JP¥1,116, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 13x in the Specialty Retail industry in Japan. Total returns to shareholders of 30% over the past three years. Aankondiging • May 22
Xebio Holdings Co., Ltd. (TSE:8281) announces an Equity Buyback for 3,000,000 shares, representing 6.79% for ¥4,000 million. Xebio Holdings Co., Ltd. (TSE:8281) announces a share repurchase program. Under the program, the company will repurchase up to 3,000,000 shares, representing 6.79% of its share capital, for ¥4,000 million worth of its common stock. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment. The share repurchase program will run until May 9, 2025. As of March 31, 2024, the company had 47,911,023 shares outstanding (excluding treasury shares) and 3,700,367 shares in treasury. Reported Earnings • May 12
Full year 2024 earnings released: EPS: JP¥58.63 (vs JP¥122 in FY 2023) Full year 2024 results: EPS: JP¥58.63 (down from JP¥122 in FY 2023). Revenue: JP¥242.4b (up 1.3% from FY 2023). Net income: JP¥2.59b (down 52% from FY 2023). Profit margin: 1.1% (down from 2.3% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Aankondiging • May 12
Xebio Holdings Co., Ltd., Annual General Meeting, Jun 27, 2024 Xebio Holdings Co., Ltd., Annual General Meeting, Jun 27, 2024. Aankondiging • Mar 27
Xebio Holdings Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024 Xebio Holdings Co., Ltd. announced that they will report fiscal year 2024 results on May 10, 2024 Upcoming Dividend • Mar 21
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 14 June 2024. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (1.3%). Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: JP¥27.71 (vs JP¥46.91 in 3Q 2023) Third quarter 2024 results: EPS: JP¥27.71 (down from JP¥46.91 in 3Q 2023). Revenue: JP¥62.1b (flat on 3Q 2023). Net income: JP¥1.23b (down 41% from 3Q 2023). Profit margin: 2.0% (down from 3.3% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Aankondiging • Dec 28
Xebio Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 09, 2024 Xebio Holdings Co., Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024 Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: JP¥0.77 (vs JP¥0.70 loss in 2Q 2023) Second quarter 2024 results: EPS: JP¥0.77 (up from JP¥0.70 loss in 2Q 2023). Revenue: JP¥57.8b (up 2.2% from 2Q 2023). Net income: JP¥34.0m (up JP¥65.0m from 2Q 2023). Profit margin: 0.1% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥15.00 per share at 2.9% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 12 December 2023. Payout ratio is a comfortable 32% and the cash payout ratio is 90%. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (1.4%). Reported Earnings • Aug 12
First quarter 2024 earnings released: EPS: JP¥44.94 (vs JP¥71.86 in 1Q 2023) First quarter 2024 results: EPS: JP¥44.94 (down from JP¥71.86 in 1Q 2023). Revenue: JP¥62.3b (up 1.3% from 1Q 2023). Net income: JP¥1.99b (down 38% from 1Q 2023). Profit margin: 3.2% (down from 5.2% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 17
Full year 2023 earnings released: EPS: JP¥124 (vs JP¥86.77 in FY 2022) Full year 2023 results: EPS: JP¥124 (up from JP¥86.77 in FY 2022). Revenue: JP¥239.3b (up 7.2% from FY 2022). Net income: JP¥5.46b (up 42% from FY 2022). Profit margin: 2.3% (up from 1.7% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Aankondiging • May 14
Xebio Holdings Co., Ltd., Annual General Meeting, Jun 29, 2023 Xebio Holdings Co., Ltd., Annual General Meeting, Jun 29, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥15.00 per share at 3.0% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 14 June 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.5%). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: JP¥46.91 (vs JP¥67.49 in 3Q 2022) Third quarter 2023 results: EPS: JP¥46.91 (down from JP¥67.49 in 3Q 2022). Revenue: JP¥62.3b (up 4.1% from 3Q 2022). Net income: JP¥2.07b (down 31% from 3Q 2022). Profit margin: 3.3% (down from 5.0% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Aankondiging • Dec 28
Xebio Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 10, 2023 Xebio Holdings Co., Ltd. announced that they will report Q3, 2023 results on Feb 10, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Full-Time Auditor Yuichi Hoshikawa was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: JP¥0.70 loss per share (vs JP¥10.59 loss in 2Q 2022) Second quarter 2023 results: JP¥0.70 loss per share (improved from JP¥10.59 loss in 2Q 2022). Revenue: JP¥56.6b (up 11% from 2Q 2022). Net loss: JP¥31.0m (loss narrowed 93% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 12 December 2022. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 3.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.5%). Aankondiging • Aug 30
Xebio Holdings Co., Ltd. to Report Q2, 2023 Results on Nov 11, 2022 Xebio Holdings Co., Ltd. announced that they will report Q2, 2023 results on Nov 11, 2022 Reported Earnings • Aug 15
First quarter 2023 earnings released: EPS: JP¥71.86 (vs JP¥47.05 in 1Q 2022) First quarter 2023 results: EPS: JP¥71.86 (up from JP¥47.05 in 1Q 2022). Revenue: JP¥61.5b (up 9.8% from 1Q 2022). Net income: JP¥3.18b (up 53% from 1Q 2022). Profit margin: 5.2% (up from 3.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Aankondiging • May 29
Xebio Holdings Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022 Xebio Holdings Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022 Reported Earnings • May 19
Full year 2022 earnings released: EPS: JP¥86.77 (vs JP¥9.32 in FY 2021) Full year 2022 results: EPS: JP¥86.77 (up from JP¥9.32 in FY 2021). Revenue: JP¥223.3b (up 10% from FY 2021). Net income: JP¥3.84b (up JP¥3.42b from FY 2021). Profit margin: 1.7% (up from 0.2% in FY 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Aankondiging • May 15
Xebio Holdings Co., Ltd., Annual General Meeting, Jun 29, 2022 Xebio Holdings Co., Ltd., Annual General Meeting, Jun 29, 2022. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Full-Time Auditor Yuichi Hoshikawa was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Apr 08
Xebio Holdings Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022 Xebio Holdings Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 15 June 2022. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 3.1%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (1.6%). Reported Earnings • Feb 12
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: JP¥67.49 (up from JP¥17.01 in 3Q 2021). Revenue: JP¥59.9b (up 2.0% from 3Q 2021). Net income: JP¥2.98b (up 297% from 3Q 2021). Profit margin: 5.0% (up from 1.3% in 3Q 2021). The increase in margin was primarily driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 16
Second quarter 2022 earnings released: JP¥10.59 loss per share (vs JP¥13.87 profit in 2Q 2021) The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2022 results: Revenue: JP¥51.2b (up 2.1% from 2Q 2021). Net loss: JP¥468.0m (down 176% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 10 December 2021. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.0%). Higher than average of industry peers (1.3%). Reported Earnings • May 17
Full year 2021 earnings released: EPS JP¥9.32 (vs JP¥9.23 in FY 2020) The company reported a mediocre full year result with weaker revenues, although profit margins were flat and earnings improved. Full year 2021 results: Revenue: JP¥202.4b (down 10% from FY 2020). Net income: JP¥412.0m (up 1.0% from FY 2020). Profit margin: 0.2% (in line with FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 12 June 2021. Trailing yield: 3.2%. Within top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (1.1%). Is New 90 Day High Low • Mar 09
New 90-day high: JP¥969 The company is up 18% from its price of JP¥823 on 09 December 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Specialty Retail industry, which is up 5.0% over the same period. Aankondiging • Mar 05
Xebio Holdings Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021 Xebio Holdings Co., Ltd. announced that they will report fiscal year 2021 results on May 14, 2021 Reported Earnings • Feb 14
Third quarter 2021 earnings released: EPS JP¥17.01 (vs JP¥4.21 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥58.7b (up 4.0% from 3Q 2020). Net income: JP¥752.0m (up 304% from 3Q 2020). Profit margin: 1.3% (up from 0.3% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Feb 05
New 90-day high: JP¥921 The company is up 29% from its price of JP¥712 on 06 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Specialty Retail industry, which is up 7.0% over the same period. Is New 90 Day High Low • Jan 20
New 90-day high: JP¥865 The company is up 21% from its price of JP¥715 on 22 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Specialty Retail industry, which is up 10.0% over the same period. Aankondiging • Sep 06
Xebio Holdings Co., Ltd. to Report Q2, 2021 Results on Nov 06, 2020 Xebio Holdings Co., Ltd. announced that they will report Q2, 2021 results on Nov 06, 2020 Aankondiging • Jun 28
Xebio Holdings Co., Ltd. to Report Q1, 2021 Results on Aug 07, 2020 Xebio Holdings Co., Ltd. announced that they will report Q1, 2021 results on Aug 07, 2020 
